ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2427

Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series

Marianna Meroni1, Maria De Santis2, Elena Generali2, Angela Ceribelli3, Marta Caprioli3, Giacomo Maria Guidelli2, Natasa Isailovic2, Gaetano Maria Fara4, Carlo Selmi2 and Maurizio Cutolo5, 1Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, 2Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 3Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, 4Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, 5Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: certolizumab pegol, outcomes, pregnancy, rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern, regarding a possible immunosuppression of the newborns, still exists. We aimed to assess the immune response and the presence of infective adverse events among the long-term followed-up offspring of RA mothers, treated by CTZ during pregnancy.

Methods: In a 4-years observational gap, we prospectively enrolled 12 newborns born to RA women, that signed an informed consent about children recruitment. The outcomes were a 24-months follow-up of the offspring health status, including infections, and, in case of routine/emergency lab test, assessment of the vaccine response according to the administered ones: esavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b and Hepatitis B virus combined vaccine (DTaP-IPV/Hib/HBV). Immune response was assessed by the following: anti-PRP antibodies (Abs) to Hib, diphtheria antitoxin and polio virus Abs, by neutralisation assays. Tetanus, pertussis and Anti-HBs Abs by ELISA (Thermo Fisher Scientific, Cleveland, OH, USA). The serology response was compared to the general population byKruskall-Wallis and reverse regression curves statistical analyses (SAS V.6.12, Chiltern International Limited, Berkshire, UK). The immunogenicity cutoffs were set according to literature references.

Results:

Among the 12 children constituting the study population, 2 had to be investigated for suspected infections and one for an episode of foreign body ingestion. According to the protocol, a blood sample taken from the planned lab tests, was sent for the assessment. Hib: the proportion of observed infants with an anti-PRP level >0.15 mg/ml was 93.2% (95% CI 86.6 to 96.7) compared with 100% (95% CI 96.4 to 100) to the reference population. The difference was 6.8% (90% CI 2.8 to 12.1). Regarding diphtheria-tetanus, pertussis, polio and HBV, the protective responses (respectively: >0.01 IU/ml, >0.01 IU/ml, >1:8 and ≥10 mIU/mL) were 99% in the study population. As the upper bound of the 90% CI was >10%, this difference confirms the non-inferiority of immune response for these children.

Conclusion: Our data are limited, since an ethical issue rises from proposing a series of blood drawns to pediatric population. Regarding the reasons of consultations, to notice that none of them suffered from serious infections requiring hospitalization or parenteral antibiotic administration. The vaccine schedule was reported as well tolerated. Their immune response, finally, was shown to be adequate and superposable to the healthy population, including the administration of an alive vaccine (polio). These results further confirm the long-term overall safety of CTZ administration during pregnancy of RA patients, regarding both the mothers and their offspring.


Disclosure: M. Meroni, None; M. De Santis, None; E. Generali, None; A. Ceribelli, None; M. Caprioli, None; G. M. Guidelli, None; N. Isailovic, None; G. M. Fara, None; C. Selmi, None; M. Cutolo, None.

To cite this abstract in AMA style:

Meroni M, De Santis M, Generali E, Ceribelli A, Caprioli M, Guidelli GM, Isailovic N, Fara GM, Selmi C, Cutolo M. Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/adequate-vaccine-response-according-to-the-italian-schedule-among-the-offspring-of-women-affected-by-rheumatoid-arthritis-and-treated-throughout-pregnancy-by-certolizumab-pegol-case-series/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adequate-vaccine-response-according-to-the-italian-schedule-among-the-offspring-of-women-affected-by-rheumatoid-arthritis-and-treated-throughout-pregnancy-by-certolizumab-pegol-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences